Renalytix reports progress in expanding US testing
9th Dec 2025 12:51
(Sharecast News) - Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London.
Read moreRenalytix shares more than double after striking US diagnostics partnership
15th Sep 2025 09:25
(Sharecast News) - Medical diagnostics firm Renalytix said on Monday that it has struck a definitive agreement with Tempus AI to accelerate the adoption of its kidneyintelX.dkd test to support early-stage risk assessment in chronic kidney disease, slow progression, and improve patient outcomes.
Read moreRenalytix Q3 revenues up 20pc
10th Apr 2025 11:41
(Sharecast News) - Precision medicine business Renalytix said on Thursday that Q3 trading was in line with expectations, delivering 20% quarter-on-quarter revenue growth as it reached "the key milestone" of processing over 1,000 billable tests within the quarter for the first time.
Read moreRenalytix terminates formal sale process
20th Aug 2024 09:58
(Sharecast News) - Renalytix, a company specialising in artificial intelligence-enabled diagnostics for kidney disease, announced the termination of its formal sale process on Tuesday.
Read moreRenalytix test gets US Medicare coverage determination
14th Jun 2024 09:27
(Sharecast News) - Renalytix announced on Friday that Medicare has issued a final local coverage determination (LCD) for its 'kidneyintelX.dkd' testing.
Read moreRenalytix surges on takeover approach
4th Mar 2024 11:28
(Sharecast News) - Renalytix surged on Monday after saying it had received an unsolicited takeover approach from "a large and well-capitalised publicly listed strategic diagnostics company".
Read moreRenalytix shares jump on draft US Medicare coverage decision
9th Feb 2024 10:38
(Sharecast News) - Renalytix shares were rocketing on Friday morning, after it announced that the Centers for Medicare and Medicaid Services (CMS) in the US had published a draft local coverage determination (LCD) for its 'KidneyIntelX' and 'kidneyintelX.dkd' testing products, outlining the coverage and pricing for the tests.
Read moreRenalytix kidney test claims allowed by US Patent Office
6th Oct 2023 11:35
(Sharecast News) - Diagnostic artificial intelligence (AI) specialist Renalytix announced an enhancement to its intellectual property portfolio for its KidneyIntelX.dkd test on Friday.
Read moreRenalytix gets KidneyIntelX included in major clinical guidelines
21st Aug 2023 12:39
(Sharecast News) - Renalytix announced on Monday that its signature solution 'KidneyIntelX' has secured a spot in the draft Kidney Disease Improving Global Outcomes (KDIGO) 2023 clinical practice guideline for the evaluation and management of chronic kidney disease.
Read moreRenalytix launches kidney disease test in Arabian Gulf countries
21st Jul 2023 16:11
(Sharecast News) - Renalytix announced the commercial availability of 'kidneyintelX.dkd' testing in six Gulf Cooperation Council (GCC) markets on Friday - Saudi Arabia, Bahrain, Qatar, Oman, Kuwait, and the United Arab Emirates.
Read moreRenalytix test gets US FDA marketing authorisation
30th Jun 2023 15:49
(Sharecast News) - Renalytix announced on Friday that the US Food and Drug Administration (FDA) had granted De Novo marketing authorisation for its 'KidneyIntelX.dkd' prognostic test.
Read moreRenalytix secures expanded coverage in Washington, DC area
22nd May 2023 12:18
(Sharecast News) - Kidney disease diagnostics developer Renalytix announced the expansion of insurance coverage in the US for its flagship product KidneyIntelX on Monday.
Read moreRenalytix reports positive study on clinical value of KidneyIntelX
19th Apr 2023 13:52
(Sharecast News) - Biotechnology company Renalytix announced the publication of new case studies in the Diabetic Nephropathy journal on Wednesday, highlighting the clinical value of 'KidneyIntelX' in risk stratification for the management of type-2 diabetes and chronic kidney disease (CKD).
Read moreRenalytix rises on publication of positive evidence
29th Nov 2022 17:14
(Sharecast News) - Renalytix announced new real-world evidence, printed in the Primary Care and Community Health publication, on Tuesday.
Read moreRenalytix reports positive outcomes from Mount Sinai
10th Jun 2022 11:48
(Sharecast News) - Renalytix updated the market on the deployment of its 'KidneyIntelX' bioprognostic testing in 1,112 adult diabetic kidney disease (DKD) patients at Mount Sinai Health System on Friday.
Read more